Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 521

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 521
---
uscum contagiosum which was subsequently approved by the FDA on January 5, 2024, and is commercially known as ZELSUVMI™.

ZELSUVMI is a topical medication for the treatment of molluscum contagiosum in adults and pediatric patients one year of age or older. The FDA approved ZELSUVMI as a novel drug for the treatment of molluscum infections. ZELSUVMI is the first and only topical prescription medication that can be applied by patients, parents, or caregivers at home, outside of a physician's office, or other medical setting to treat this highly contagious viral skin infection.

Through the Novan Acquisition, LNHC holds an IP portfolio that consisted of over 45 U.S. patents, 120 non-U.S. patents, and 25 pending patent applications worldwide along with substantial know-how and trade secrets. In addition to ZELSUVMI, this IP portfolio provides material coverage for the NITRICIL platform technologies, licensed products and product candidates. There are 14 issued U.S. patents covering ZELSUVMI which are expected to be listed in the Orange Book and which are expected to expire beginning in 2026 and ending in 2035 (or potentially 2037 with patent extension).

**Note 2: Basis of Presentation and Significant Accounting Policies**

#### Basis of Presentation
Unless the context otherwise requires, “LNHC” or the “Company,” for periods after the Novan Acquisition, refers to LNHC, Inc. (“Successor”), and for the periods prior to the Novan Acquisition, refers to the corresponding part of Novan's business (“Predecessor”).

As a result of the Novan Acquisition accounting, the results of operations, financial position and cash flows of the Predecessor and Successor are not directly comparable. The accompanying financial statements include a Predecessor period (which includes the period from January 1, 2023 through September 27, 2023 (date of Novan Acquisition), and a Successor period (from September 28, 2023 through December 31, 2024). A black line between the Successor and Predecessor periods has been placed in the financial statements and in the tables to the notes to the financial statements to highlight the lack of comparability between these two periods.

The Successor's and Predecessor's financial statements have been prepared on a stand-alone basis, in conformity with United States generally accepted accounting principles (U.S. GAAP), and are derived from consolidated accounting